Anixa Biosciences Aktie [WKN DE: A2N6ZF / ISIN: US03528H1095]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Anixa Biosciences Inc Registered Shs

08.05.24		Anixa Inks Joint Development Agreement With Cleveland Clinic To Develop Novel Cancer Vaccines (RTTNews)
14.12.23		Anixa Biosciences to Present at Biotech Showcase 2024 (PR Newswire)
07.12.23		Anixa Biosciences Announces Positive Data From Phase 1 Study Of Breast Cancer Vaccine; Stock Up (RTTNews)
07.12.23		Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine (PR Newswire)
06.12.23		Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine (PR Newswire)
27.11.23		Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology (PR Newswire)
31.10.23		Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference (PR Newswire)
23.10.23		Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire)
13.10.23		Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
03.10.23		Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology (PR Newswire)
19.09.23		Anixa Biosciences Establishes Cancer Business Advisory Board (PR Newswire)
31.08.23		Anixa Biosciences to Participate in September Investor Conferences (PR Newswire)
28.08.23		Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
14.08.23		Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit (PR Newswire)
07.08.23		Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial (PR Newswire)
27.07.23		Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology (PR Newswire)
11.07.23		Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology (PR Newswire)
22.05.23		Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
17.04.23		Anixa Biosciences Clarifies Poster Presentation on Company Website (PR Newswire)
17.04.23		Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine (PR Newswire)
27.03.23		Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting (PR Newswire)
13.03.23		Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank (PR Newswire)
02.03.23		Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders (PR Newswire)
27.02.23		Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology (PR Newswire)
21.02.23		Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board (PR Newswire)
19.12.22		Anixa Biosciences to Present at Biotech Showcase 2023 (PR Newswire)
08.12.22		Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine (PR Newswire)
08.11.22		Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium (PR Newswire)
31.10.22		Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy (PR Newswire)
26.10.22		Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic (PR Newswire)
10.10.22		Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire)
12.09.22		Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium (PR Newswire)
31.08.22		Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
15.08.22		Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial (PR Newswire)
21.07.22		Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology (PR Newswire)
21.06.22		Anixa Publishes Scientific Paper On Preventative Ovarian Cancer Technology (RTTNews)
21.06.22		Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology (PR Newswire)
13.06.22		Pre-market Movers: BLUE, MSTR, VALN, RDBX, DBVT… (RTTNews)
05.05.22		Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference (PR Newswire)
28.04.22		Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
06.04.22		Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at The 4th International Workshop on CAR-T 2022 (PR Newswire)
30.03.22		Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center (PR Newswire)
17.03.22		Anixa Biosciences to Participate in the 2022 Virtual Growth Conference Hosted by M-Vest, a Division of Maxim Group LLC (PR Newswire)
07.03.22		Pre-market Movers: HUSA, BBBY, NINE, IMPP, MXC… (RTTNews)
25.01.22		Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine (PR Newswire)
24.01.22		Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor (PR Newswire)
16.12.21		Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect Conference (PR Newswire)
07.12.21		Anixa : COVID-19 Compounds Expected To Be Effective Against Omicron And Delta Variants (RTTNews)
07.12.21		Anixa Biosciences and MolGenie Announce that their COVID-19 Compounds are Expected to be Effective Against the Omicron Variant (PR Newswire)
26.10.21		Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 12:34
Kaufwert:	EUR
	Hinzufügen Speichern